Published Date: 17 Mar 2023
NEW DELHI: The National Medical Commission (NMC) has requested all medical schools to schedule examination appointments for Broad...
Read Full NewsThe rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.
A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.
New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.
Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.
This rheumatology month in review emphasizes new data from the ACR Convergence.
New data support firsekibart's efficacy over colchicine for preventing acute gout flares.
A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.
1.
Patients face high out-of-pocket costs after incident cancer diagnosis
2.
In a study, immune detection of oral cancers is linked to obesity.
3.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
4.
Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.
5.
Common intracellular toxin could help fight leukemia
1.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
2.
The Latest Research on Chronic Granulomatous Disease and Promising New Treatments
3.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
4.
Florinef: Understanding Its Uses and Side Effects
5.
Uncovering the Subtle Signs of Leukemia: A Guide to Early Detection
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation